Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation
Cardiac glycosides are approved for the treatment of heart failure as Na+/K+ pump inhibitors. Their repurposing in oncology is currently investigated in preclinical and clinical studies. However, the identificati...
Source: Journal of Experimental and Clinical Cancer Research - Category: Cancer & Oncology Authors: Elodie M. Da Costa, Gregory Armaos, Gabrielle McInnes, Annie Beaudry, Ga ël Moquin-Beaudry, Virginie Bertrand-Lehouillier, Maxime Caron, Chantal Richer, Pascal St-Onge, Jeffrey R. Johnson, Nevan Krogan, Yuka Sai, Michael Downey, Moutih Rafei, Meaghan Boi Tags: Research Source Type: research